You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Tau Immunotherapies for Alzheimer’s Disease and Related Tauopathies: Progress and Potential Pitfalls

[Journal of Alzheimer’s Disease 64(S1), 2018, S555-S565, DOI:10.3233/JAD-179937

https://content.iospress.com/articles/journal-of-alzheimers-disease/jad179937

On page S560 and 561 only four of the six passive trials consisting of antibodies were printed. The points 5 and 6 were excluded from the published article. The full listing, with point 5 and 6 in bold, is given below:

The six passive trials consist of antibodies targeting:

1) tau8– 19 in healthy subjects and PSP patients, that was developed by iPerian and subsequently by Bristol-Meyers Squibb and has now been licensed to Biogen [38, 85, 86]. Currently named BIIB092 (previously BMS-986168 and IPN007), it is in Phase I-II for PSP;

2) tau25– 30 in AD (Phase II, [87]) and PSP (Phase II; [88]). It was developed by C2N Diagnostics, LLC (C2N 8E12; [32, 89]) and has been licensed to AbbVie (ABBV-8E12);

3) an unidentified epitope that may be phosphoserine 409 (RO7105705) in healthy subjects and AD patients [72, 90];

4) an unidentified epitope (LY3303560) in subjects that are healthy, or with mild cognitive impairments or AD (Phase I, [91, 92]) that is likely a humanized form of the conformational antibody MC1 [73, 93], which as mentioned above has been effective in different mouse studies [20, 31];

5) The middle region of tau in healthy subjects and AD patients (JNJ-63733657) [94, 95], and;

6) Tau235-246 in healthy subjects (UCB0107) [95, 96].

On Page S565, in the Reference section, second column, there were three missing references. The correct listing of references is (with the previous three missing references in bold):

[94] ClinicalTrials.gov (2018) A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects with Alzheimers’ Disease. https://clinicaltrials.gov/ct2/show/NCT03375697. US National Library of Medicine.

[95] Rogers MB (2018) To block tau’s proteopathic spread, antibody must attack its mid region. Alzforumhttps://www.alzforum.org/news/conference-coverage/block-taus-proteopathic-spread-antibody-must-attack-its-mid-region.

[96] ClinicalTrials.gov (2018) A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects. https://clinicaltrials.gov/ct2/show/NCT03464227.

[97] Saint-Aubert L, Lemoine L, Chiotis K, Leuzy A, Rodriguez-Vieitez E, Nordberg A (2017) Tau PET imaging: Present and future directions. Mol Neurodegener 12, 19.

[98] Hall B, Mak E, Cervenka S, Aigbirhio FI, Rowe JB, O’Brien JT (2017) In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Res Rev 36, 50-63.

On Page S561, right column, lines 7 and 10, references 94 and 95 should then be changed to references 97 and 98. The correct sentences are:

Advances in tau brain imaging have now resulted in several promising β-sheet dye compounds that appear to be selective for tau aggregates, although non-specific binding has now been reported for some of them and their use discontinued [97, 98]. Also, these probes are not good at detecting non-AD tauopathies, suggesting some structural differences in the tau lesions [97, 98].

Finally, one ongoing passive tau antibody trial was missed. BIIB076, against an unidentified epitope, originally developed by Neurimmune (NI-105, 6C5), was acquired by Biogen and is currently in Phase I trial in healthy subjects and AD patients (NCT03056729). It has shown target engagement without apparent toxicity in cynomolgus monkeys (Czerkowicz J et al., Alzheimer’s & Dementia, July 2017, Vol. 13, Issue 7, Supplement,page P1271).